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ABSTRACT
Immune thrombocytopenia (ITP) related to Mycoplasma pneumoniae infection is a rare condition and usually associated with a severe clinical 
course. We here report a case of a young man with a clinical diagnosis of severe ITP secondary to M. pneumoniae infection. The clinical 
features, therapy and outcome are presented.
LEARNING POINTS
• Immune thrombocytopenia (ITP) related to Mycoplasma pneumoniae infection is a rare condition.
• ITP secondary to M. pneumoniae infection appears to be associated with a more severe and refractory clinical course.
•	 It	remains	unclear	whether	specific	anti-Mycoplasma antibiotic therapy is associated with a milder clinical course and a better prognosis.
KEYWORDS
Immune thrombocytopenia, Mycoplasma pneumoniae, rituximab
INTRODUCTION
Immune thrombocytopenia (ITP) is one of the more common causes of thrombocytopenia in otherwise healthy adults. Thrombocytopenia 
associated with M. pneumoniae infection is a rare condition which usually has a severe course. We report the case of a young man with 
a clinical diagnosis of severe ITP that was associated with M. pneumoniae infection. Extra-pulmonary features of M. pneumoniae infection 
occur in 20–25% of cases, with the most commonly associated haematological abnormality being haemolytic anaemia due to the formation 
of cold agglutinin antibodies against erythrocyte I antigen[1]. Thrombocytopenia associated with M. pneumoniae is usually associated with 
thrombotic thrombocytopenic purpura or disseminated intravascular coagulation, but association with ITP is rare.
CASE DESCRIPTION
A 24-year-old male college student was admitted to the emergency department with a 1-day history of reddish lesions on both legs (Fig. 1), a 
tongue haematoma following accidental bite (Fig. 2) and two small back bruises, self-induced after pinching himself. He remembered having 
odynophagia and serous rhinorrhoea without a cough or fever 2 weeks before admission. With a history of infectious mononucleosis at the 
age of 16, he had had recurrent tonsillitis ever since. He was physically very active and his medication history included protein supplements 
and	a	one-time-only	use	of	sildenafil.
European Journal
of Case Reports in
Internal Medicine
DOI: 10.12890/2018_000817 European Journal of Case Reports in Internal Medicine © EFIM 2018
Initial evaluation revealed normal vital signs, with a body temperature of 36.7°C, blood pressure of 132/61 mmHg, pulse rate of 54 beats/
min and O
2
 saturation of 100% on room air. He had petechial and purpuric lesions on both legs, slightly palpable hepatosplenomegaly and no 
identifiable	adenopathies.	The	remaining	physical	examination	was	normal.
Complete blood count showed haemoglobin of 14.6 g/dl, leucocyte count of 5.7×109 cells/l and platelet count of 3×109 cells/l. Coagulation, 
liver	and	renal	studies	were	normal.	CRP	was	1.15	mg/dl.	A	peripheral	blood	smear	confirmed	severe	thrombocytopenia	without	abnormal	
cells.	A	chest	x-ray	did	not	show	any	signs	of	pleuroparenchymal	lung	disease	and	abdominal	ultrasound	confirmed	the	presence	of	moderate	
homogeneous hepatosplenomegaly.
A presumptive diagnosis of ITP was made, corticoid treatment was promptly initiated and the patient was hospitalized. No platelet count 
response was seen following a 3-day course of methylprednisolone 1 g IV. Oral prednisolone 1 mg/kg/day and a 3-day course of intravenous 
immunoglobulin (IVIG) 1 g/kg was therefore initiated with an increase in platelet count to 48×109 cells/l the day after. However, on the very 
next day, the platelet count dropped once again to 2×109 cells/l. A second 3-day course of methylprednisolone 1 g IV in association with 4 
more days of IVIG 1 g/kg was given with no platelet response. The patient remained clinically stable until the 11th day of hospitalization 
when he presented with epistaxis (Fig. 3), gingival haemorrhage, vascular puncture site haematoma (Fig. 4) and new petechiae on the face 
and trunk. Prednisolone dosage was increased to 1.5 mg/kg/day and the anti-CD20 monoclonal antibody rituximab 375 mg/m2 IV was also 
initiated. Bone marrow examination revealed normal cellularity with megakaryocytic hyperplasia but no cell abnormalities, compatible with 
the diagnosis of ITP. A thoraco-abdomino-pelvic CT scan did not show any lymphadenopathies or lesions suggestive of a neoplastic process.
Serological testing for EBV, CMV, HCV, HBV, HIV, HSV and parvovirus B19 was negative for acute infection. A urea breath test for Helicobacter 
pylori was negative. Assays for ANA, dsDNA, rheumatoid factor, anticardiolipin, lupus anticoagulant and anti-beta-2 glycoprotein were also 
negative. Antiplatelet antibodies were positive and a positive M. pneumoniae IgM titre was found. ITP secondary to M. pneumoniae infection 
was assumed, and clarithromycin 500 mg twice a day was added to the treatment regimen.
By the 14th day of hospitalization the platelet count was still 4×109 cells/l and the patient presented with gross haematuria. As a consequence, 
two pools of platelets were given and he was transferred to the intermediate care unit for closer observation. He became hypertensive 
(blood pressure of 170/90 mmHg), anaemic (with haemoglobin dropping to 8.9 g/dl) and developed a constant headache and occasional 
haemolacria (Fig. 5). A cranial CT scan excluded any haemorrhagic lesions.
Six days after the second dose of rituximab (on the 24th day of hospitalization), the platelet count slowly started to rise to 21×109 cells/l.
Figure 1. Reddish lesions on both legs suggestive of petechiae and 
purpura of the inferior limbs
Figure 2. Tongue haematoma
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Given the subsequent resolution of haematuria and other haemorrhagic dyscrasia, the dose of oral prednisolone was reduced to 1 mg/kg/
day and the patient was transferred back to the medicine ward, where he completed treatment with rituximab.
From the 25th day of hospitalization onwards, the platelet count gradually increased, as did haemoglobin values. The patient was discharged 
on the 28th day after admission with a platelet count of 229×109 cells/l and no signs of blood dyscrasia. He returned for 2-week follow-up 
asymptomatic and with a platelet count of 273×109 cells/l, slowly tapering oral prednisolone as advised upon discharge.
DISCUSSION
Haematological abnormalities associated with Mycoplasma infection are widely described, but association with ITP is rarely reported[2].
We	identified	10	similar	case	reports	in	a	literature	research.	Table 1 summarizes the clinical features and outcomes of those cases. Most 
patients (7 out of 10) were male and the mean age was 18 years (ranging from 7 months to 64 years). The most common clinical presentation 
was respiratory infection (cough, fever and dyspnoea) and mild haemorrhagic manifestations (petechiae, purpura and epistaxis). Two 
patients presented with more severe forms of haemorrhage (haemoptysis, haematuria and haematochezia), while three patients did not 
have any haemorrhagic symptoms at all. The mean platelet count on admission was 11×103 cells/l. Apart from one patient, all subjects 
underwent corticosteroid therapy. In three of them IGIV therapy was given as well. Empiric antimicrobial therapy was administered to 
eight patients, targeting atypical bacteria, in most cases through macrolide usage. Interestingly, none of the patients required rituximab. 
The mean time required for platelets to rise above 150×103 cells/l was 21 days. In most cases evidence for Mycoplasma infection came 
from	a	complement	fixation	test,	cold	agglutinin	test	or	IgM	titre.	Two	patients	experienced	intracranial	haemorrhage	and	died.	Although	
incompletely	 understood,	 the	 pathogenesis	 of	 ITP	 is	 thought	 to	 involve	 the	 formation	 of	 specific	 autoantibodies	 against	 platelet	 cell	
membrane glycoproteins, more commonly GPIIb/IIIa [3]. 
In up to 60% of patients, M. pneumoniae infection manifests itself only by odynophagia and rhinorrhoea, as in our patient.
Several physiopathological mechanisms have been described to explain the production of antiplatelet antibodies following Mycoplasma 
infection, such as molecular mimicry, the development of immune complexes that may cause platelet aggregation, serotonin release, and 
clearance of platelets [4] and even direct binding of Mycoplasma to the platelets, generating a complex that is then recognized as foreign by 
the immune system.
Secondary ITP associated with M. pneumoniae infection appears to have a more severe clinical course and, to some extent, to be a refractory 
disease, as evidenced by the referenced cases and our own.
About	66%	of	patients	with	ITP	respond	to	steroid	therapy	after	1–2	weeks.	Our	patient	was	found	to	be	corticosteroid	resistant	which	first	
led to the need to initiate IGIV therapy and later, given the poor clinical response, to second-line therapy with rituximab.
Figure 3. Epistaxis Figure 4. Vascular puncture site haematoma Figure 5. Haemolacria
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Rituximab is a monoclonal antibody directed against the B cell surface protein CD20. Response to this therapy can occur within a week 
but may take up to 2 months. In this case our patient had a partial response on day 14 and a complete response after 15 days of rituximab 
therapy.
Specific	anti-Mycoplasma therapy was initiated but, in our case, had no apparent effect on the clinical course or outcome, so given the very 
few	cases	described,	we	cannot	evaluate	the	benefit	of	this	particular	therapy.
CONCLUSION
Considering the clinical features described above, ITP secondary to M. pneumoniae infection appears to be associated with a more severe 
and	refractory	clinical	course.	 It	remains	unclear	whether	specific	anti-Mycoplasma antibiotic therapy is associated with a milder clinical 
course and a better prognosis.
Case Age (yrs) Sex Clinical Presentation Platelets on 
admission 
(×103 cells/l)
Mycoplasma
testing
Complications Treatment Time to platelets
 >150 
(×103 cells/l)
Current case 24, Male Petechiae and purpura, 
odynophagia and serous 
rhinorrhoea 
2 weeks previously
3 IgM 29.9 Epistaxis, gingival 
haemorrhage, 
haematuria, 
haemolacria, 
anaemia and
headache
Methylprednisolone, 
IVIG, prednisolone, 
rituximab,
 clarithromicin
28 days
Tsai et al.[5] 0,7,  Female Cough, fever, dyspnoea 
(pneumonia) and petechiae
14 Complement 
fixation test 1:4;
cold agglutinin 
1:128
None Prednisolone,
 minocycline
14 days
Miller et al.[6] 44, Male Cough, fever (pneumonia), 
haematuria
7 Complement 
fixation test 1:4 to 
1:32; cold 
agglutinin 1:128
Brain stem 
haemorrhage, 
death on day 14
Erythromycin, 
cefotaxime,
 amikacin, 
methylprednisolone
Never
Veenhoven et al.[7] 17, Male Cough, fever, dyspnoea 
(pneumonia) and petechiae
25 Complement 
fixation test 1:64; 
IgM+cold 
agglutinin 32–256
None Prednisolone, 
erythromycin
3 months
Beattie[8] 4, Male Cough, fever (pneumonia) 4 IgM 80–320 Purpura, epistaxis 
and haematuria
IGIV Not mentioned, 
42×103 cells/l
 on day 5
Pugliese et al.[9] 7, Male Sinusitis, fever <18 ELISA 1.01; 
cold agglutinin 1:64
Headache, 
vomiting, diarrhoea
Ceftriaxone,
erythromycin, 
prednisone
14 days
Isoyama et al.[10] 8, Male Rhinorrhoea, cough, 
epistaxis, petechiae and 
haematoma of the skin
2 ELISA 4 to >1.5; 
3 positive cultures
Epistaxis,
 haematuria and 
haematochezia
Prednisone, IVIG 14 days
Venkatesan et al. [11] 21, Male Cough, fever (pneumonia),
 purpura, haemoptysis, 
haematuria and 
haematochezia
6 Complement 
fixation test 
1:8000; 
total anti-mycoplasma 
1:5120
Intracranial
haemorrhage; 
death on day 2
Cefotaxime, 
methylprednisolone, 
erythromycin
Never
Scimeca and James-
Herry[12]
7, Male Otitis media, fever 5 Mycoplasma 
pneumoniae titre 
and antibody
Petechiae Amoxicillin, 
erythromycin, 
prednisone
1 week
Okoli et al.[13] 64, Female Cough, dyspnoea, epistaxis, 
purpura and bruising
3 IgM+cold agglutinin None Moxifloxacin, 
dexamethasone 
40 mg
3 months
Aviner et al.[14] 7, Female Cough, fever (pneumonia), 
petechiae and 
purpura
2 IgM+total 
anti-mycoplasma 
1:64
Haemoptysis IVIG, prednisolone, 
clarithromycin
2 months
Table 1. Clinical features and outcomes of Mycoplasma infection-associated immune thrombocytopenia
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